Amgen Optimistic Over Inflammation Biosimilars Ahead Of Ustekinumab

Patient Enrollment Complete For Phase III Stelara Biosimilar Study

 
• By Dean Rudge
  
Growth
Amgen is eyeing growth for inflammation biosimilars • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products